Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term macitentan in Fontan-palliated adults and adolescents
2018-002821-45Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of macitentan in Cardiovascular Malformation (CVM) and heart failure (HF), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Long-term safety and tolerability of macitentan. Started Oct 2018; status: completed.
02
Drugs
macitentan
03
Conditions
Cardiovascular Malformation (CVM)heart failure (HF)
Beyond the preview
Go deeper on 2018-002821-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002821-45.